The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition
Open accessAbstract
Background: The role of both microglial activation and alpha-synuclein deposition in Parkinson's disease remain unclear. We have tested the hypothesis that if microglia play a primary role in Parkinson's disease pathogenesis, the microglial "activated" phenotype should be associated with histopathological and/or clinical features of the disease. Methods: We have examined microglial MHC class II expression, a widely used marker of microglial activation, the occurrence of CD68-positive phagocytes and alpha-synuclein immunoreactivity in post-mortem human substantia nigra affected by idiopathic Parkinson's disease (PD). Using semi-quantitative severity ratings, we have examined the relationship between microglial activation, alpha-synuclein deposition, classical neuropathological criteria for PD, subtype of the disease and clinical course. Results: While we did not observe an association between microglial MHC class II expression and clinical parameters, we did find a correlation between disease duration and the macrophage marker CD68 which is expressed by phagocytic microglia. In addition, we observed a significant correlation between the degree of MHC class II expression and alpha-synuclein deposition in the substantia nigra in PD. Conclusion: While microglia appeared to respond to alpha-synuclein deposition, MHC class II antigen expression by microglia in the substantia nigra cannot be used as an indicator of clinical PD severity or disease progression. In addition, a contributory or even causative role for microglia in the neuronal loss associated with PD as suggested by some authors seems unlikely. Our data further suggest that an assessment of microglial activation in the aged brain on the basis of immunohistochemistry for MHC class II antigens alone should be done with caution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dysregulation of microglia functions contribute to the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD) (6–8), Parkinson’s disease (PD) (9–12) and Huntington’s disease (HD) (13–15).”
From An environment-dependent transcriptional network specifies human microglia identity (2017) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Microglia accumulate near α-synuclein deposits and become proinflammatory in a manner dependent on receptors that also bind Aβ, such as CD36 and TLR263–65.”
From Microglia in neurodegeneration (2018) · cites this paper as [63]
In the citing paper
“Microglia also phagocytose α-synuclein, the constituent protein of Lewy bodies in Parkinson’s and Lewy Body dementias, and become pro-inflammatory in the process, expressing cytokines (IL1β, IL6, TNFα), reactive oxygen species (ROS) and prostaglandin synthesising cyclooxygenase 2 (COX2) [24,25,26].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Self-citationMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Liu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035048 · Cited by 1,095
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791
Research works printed but not linked: 1
- Graeber MB: Glial inflammation in neurodegenerative diseases. 8th Annual Congress of the British Society for Immunology, Harrogate, 5–8 December 2000, Immunology. 2000, Oxford: Blackwells, Abstract, Supplement
Cited by
Sorted by citations
Items 101–200 of 416
Trudler, D., Weinreb, O., Mandel, S. A., Youdim, M. B. H., & Frenkel, D. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12633 · Cited by 111
Lv, Q.-K., Tao, K., Wang, X.-B., Yao, X., Pang, M., Liu, J., Wang, F., & Liu, C. (2023) · Inflammation Research · doi:10.1007/s00011-022-01676-x · Cited by 117
Jeong, H., Jou, I., & Joe, E.-H. (2010) · Experimental & Molecular Medicine · doi:10.3858/emm.2010.42.12.085 · Cited by 104
Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
Maki, T., Hayakawa, K., Pham, L. D., Xing, C., Lo, E. H., & Arai, K. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312030004 · Cited by 103
Benskey, M. J., Sellnow, R. C., Sandoval, I. M., Sortwell, C. E., Lipton, J. W., & Manfredsson, F. P. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00036 · Cited by 102
Beach, T. G., Sue, L. I., Walker, D. G., Lue, L. F., Connor, D. J., Caviness, J. N., Sabbagh, M. N., & Adler, C. H. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0250-5 · Cited by 104
Doorn, K. J., Goudriaan, A., Blits‐Huizinga, C. T., Bol, J. G. J. M., Rozemüller, A. J. M., Hoogland, P. V. J. M., Lucassen, P. J., Drukarch, B., van de Berg, W. D. J., & van Dam, A. (2013) · Brain Pathology · doi:10.1111/bpa.12088 · Cited by 104
Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease
Doorn, K. J., Lucassen, P. J., Boddeke, H. W. G. M., Prins, M., Berendse, H. W., Drukarch, B., & van Dam, A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.005 · Cited by 98
Roodveldt, C., Labrador‐Garrido, A., González‐Rey, E., Fernández-Montesinos, R., Caro, M., Lachaud, C. C., Waudby, C. A., Delgado, M., Dobson, C. M., & Pozo, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013481 · Cited by 99
Miller, R. L., Sun, G. Y., & Sun, A. Y. (2007) · Brain Research · doi:10.1016/j.brainres.2007.06.046 · Cited by 99
Roodveldt, C., Labrador‐Garrido, A., González‐Rey, E., Lachaud, C. C., Guilliams, T., Fernández-Montesinos, R., Benitez-Rondan, A., Robledo, G., Hmadcha, A., Delgado, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079160 · Cited by 99
Immunotherapy for Parkinson’s disease
Schwab, A. D., Thurston, M. J., Machhi, J., Olson, K. E., Namminga, K. L., Gendelman, H. E., & Mosley, R. L. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104760 · Cited by 101
Immune responses in the Parkinson's disease brain
Weiss, F. C., Labrador‐Garrido, A., Dzamko, N. L., & Halliday, G. M. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105700 · Cited by 100
Microvascular Changes in Parkinson’s Disease- Focus on the Neurovascular Unit
Paul, G., & Elabi, O. F. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.853372 · Cited by 98
Moran, L. B., & Graeber, M. B. (2008) · Neurogenetics · doi:10.1007/s10048-007-0116-y · Cited by 95
Self-citationImmunological features of α‐synuclein in Parkinson's disease
Roodveldt, C., Christodoulou, J., & Dobson, C. M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00450.x · Cited by 97
Neuroinflammation in Multiple System Atrophy: Response to and Cause of α-Synuclein Aggregation
Vieira, B. D. M., Radford, R. A., Chung, R. S., Guillemin, G. J., & Pountney, D. L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00437 · Cited by 93
Depboylu, C., Schafer, M. K.-H., Arias-Carrión, Ó., Oertel, W. H., Weihe, E., & Höglinger, G. U. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31820805b9 · Cited by 91
Navarrete, F., García‐Gutiérrez, M. S., Aracil-Fernández, A., Lanciego, J. L., & Manzanares, J. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0603-x · Cited by 90
Decoding Mast Cell-Microglia Communication in Neurodegenerative Diseases
Sandhu, J. K., & Kulka, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031093 · Cited by 90
Oligodendroglial α‐synucleinopathy‐driven neuroinflammation in multiple system atrophy
Hoffmann, A., Ettle, B., Battis, K., Reiprich, S., Schlachetzki, J. C. M., Masliah, E., Wegner, M., Kuhlmann, T., Riemenschneider, M. J., & Winkler, J. (2019) · Brain Pathology · doi:10.1111/bpa.12678 · Cited by 83
Chutna, O., Gonçalves, S. A., Villar‐Piqué, A., Guerreiro, P. S., Marijanovic, Z., Mendes, T., Ramalho, J. S., Emmanouilidou, E., Ventura, S., Klucken, J., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu391 · Cited by 82
Proteomic Studies of Nitrated Alpha-Synuclein Microglia Regulation by CD4+CD25+ T Cells
Reynolds, A. D., Stone, D. K., Mosley, R. L., & Gendelman, H. E. (2009) · Journal of Proteome Research · doi:10.1021/pr9001614 · Cited by 83
Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson’s Disease
Cardinale, A., Calabrese, V., de Iure, A., & Picconi, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126517 · Cited by 79
Golovko, M. Y., Barceló‐Coblijn, G., Castagnet, P. I., Austin, S. A., Combs, C. K., & Murphy, E. J. (2008) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-0008-y · Cited by 81
Microglia in dementia with Lewy bodies
Streit, W. J., & Xue, Q. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.10.012 · Cited by 78
Neurovascular Inflammaging in Health and Disease
Mészáros, Á., Molnár, K., Nógrádi, B., Hernádi, Z., Nyúl‐Tóth, Á., Wilhelm, I., & Krizbai, I. A. (2020) · Cells · doi:10.3390/cells9071614 · Cited by 86
Gene Therapy in Parkinsonʼs Disease
Feng, L., & Maguire‐Zeiss, K. A. (2010) · CNS Drugs · doi:10.2165/11533740-000000000-00000 · Cited by 80
Role of Microglia Adenosine A2AReceptors in Retinal and Brain Neurodegenerative Diseases
Santiago, A. R., Baptista, F. I., Santos, P. F., Cristóvão, G., Ambrósio, A. F., Cunha, R. A., & Gomes, C. A. (2014) · Mediators of Inflammation · doi:10.1155/2014/465694 · Cited by 81
CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson’s disease
Li, Y., Niu, M., Zhao, A., Kang, W., Chen, Z., Luo, N., Zhou, L., Zhu, X., Lu, L., & Liu, J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1646-6 · Cited by 79
The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson’s Disease
Titze-de-Almeida, S. S., Soto‐Sánchez, C., Fernández, E., Koprich, J. B., Brotchie, J. M., & Titze‐de‐Almeida, R. (2020) · Cells · doi:10.3390/cells9040841 · Cited by 81
l ‐DOPA‐induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?
Carta, A. R., Mulas, G., Bortolanza, M., Duarte, T. T., Pillai, E., Fisone, G., Raisman‐Vozari, R., & Bel, E. A. D. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13482 · Cited by 80
Potential Treatment of Parkinson’s Disease with Omega-3 Polyunsaturated Fatty Acids
Li, P., & Song, C. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1735143 · Cited by 74
Microglial pathology in Down syndrome
Xue, Q., & Streit, W. J. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0864-5 · Cited by 75
Garcia, P., Jürgens‐Wemheuer, W., Uriarte Huarte, O., Michelucci, A., Masuch, A., Brioschi, S., Weihofen, A., Koncina, E., Coowar, D., Heurtaux, T., et al. (2022) · Glia · doi:10.1002/glia.24149 · Cited by 65
dos Santos, M. G., Schimith, L. E., André‐Miral, C., Muccillo-Baisch, A. L., Arbo, B. D., & Hort, M. A. (2022) · Neurotoxicity Research · doi:10.1007/s12640-021-00450-x · Cited by 75
Early Stages for Parkinson’s Development: α-Synuclein Misfolding and Aggregation
Yu, J., & Lyubchenko, Y. L. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9115-5 · Cited by 71
Neuroinflammation in Synucleinopathies
Lim, S., Chun, Y., Lee, J. S., & Lee, S. (2016) · Brain Pathology · doi:10.1111/bpa.12371 · Cited by 70
Lei, Q., Wu, T., Wu, J., Hu, X., Guan, Y., Wang, Y., Yan, J., & Shi, G. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12374 · Cited by 74
Boas, S. M., Joyce, K. L., & Cowell, R. M. (2021) · Antioxidants · doi:10.3390/antiox11010008 · Cited by 70
Mackie, P. M., Lebowitz, J., Saadatpour, L., Nickoloff, E., Gaskill, P. J., & Khoshbouei, H. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.03.020 · Cited by 75
Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates
Barkholt, P., Sánchez-Guajardo, V., Kirik, D., & Romero‐Ramos, M. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.02.004 · Cited by 69
Fowler, A. J., Hebron, M. L., Missner, A. A., Wang, R., Gao, X., Kurd-Misto, B. T., Liu, X., & Moussa, C. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0266-z · Cited by 70
Alpha-Synuclein and Lipids: The Elephant in the Room?
Sarchione, A., Marchand, A., Taymans, J., & Chartier‐Harlin, M. (2021) · Cells · doi:10.3390/cells10092452 · Cited by 72
Zhang, Z., Zhou, Y.-J., Gu, P., Zhao, W., Chen, H., Wu, R.-Y., Zhou, L., Cui, Q.-Z., Sun, S.-K., Zhang, L., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.368300 · Cited by 68
Singhal, N. K., Srivastava, G., Agrawal, S., Jain, S. K., & Singh, M. P. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8225-x · Cited by 65
Oh, S. H., Kim, H., Park, H.-J., Shin, J. Y., Kim, D. Y., & Lee, P. H. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2016-0111 · Cited by 68
Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease
Saha, P., Kathuria, H., & Pandey, M. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.021 · Cited by 67
How the immune system shapes neurodegenerative diseases
Mason, H. D., & McGavern, D. B. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.08.001 · Cited by 67
Farrell, K., Krishnamachari, S., Villanueva, E., Lou, H., Alerte, T. N. M., Peet, E., Drolet, R. E., & Perez, R. G. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12481 · Cited by 63
Inflammatory Pathways in Parkinson’s Disease; A BNE Microarray Study
Durrenberger, P. F., Grünblatt, E., Fernando, F. S., Monoranu, C. M., Evans, J., Riederer, P., Reynolds, R., & Dexter, D. T. (2012) · Parkinson's Disease · doi:10.1155/2012/214714 · Cited by 63
Self-citationWhite matter damage and systemic inflammation in Parkinson’s disease
Chiang, P., Chen, H.-L., Lu, C., Chen, P.-C., Chen, M., Yang, I.-H., Tsai, N., & Lin, W. (2017) · BMC Neuroscience · doi:10.1186/s12868-017-0367-y · Cited by 63
Thomsen, M. B., Ferreira, S. A., Schacht, A. C., Jacobsen, J., Simonsen, M., Betzer, C., Jensen, P. H., Brooks, D. J., Landau, A. M., & Romero‐Ramos, M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105229 · Cited by 67
The systemic immune response in Parkinson’s disease: focus on the peripheral immune component
Lauritsen, J., & Romero‐Ramos, M. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.07.005 · Cited by 66
Lecca, D., Janda, E., Mulas, G., Diana, A., Martino, C., Angius, F., Spolitu, S., Casu, M. A., Simbula, G., Boi, L., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14214 · Cited by 62
Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies
Terkelsen, M. H., Klæstrup, I. H., Hvingelby, V. S., Lauritsen, J., Pavese, N., & Romero‐Ramos, M. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223245 · Cited by 64
Flores‐León, M., & Outeiro, T. F. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02601-0 · Cited by 62
Alpha synuclein in hematopoiesis and immunity
Pei, Y., & Maitta, R. W. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02590 · Cited by 62
Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia
Giorgi, F. S., Biagioni, F., Galgani, A., Pavese, N., Lazzeri, G., & Fornai, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228630 · Cited by 63
Microglial glutamate release evoked by α‐synuclein aggregates is prevented by dopamine
Pereira, M. D. S., Acuña, L., Hamadat, S., Rocca, J., González‐Lizárraga, F., Chehín, R. N., Sepulveda-Diaz, J. E., Bel, E. A. D., Raisman‐Vozari, R., & Michel, P. P. (2018) · Glia · doi:10.1002/glia.23472 · Cited by 60
Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson’s Disease
Williams, G. P., Schonhoff, A. M., Sette, A., & Arlehamn, C. S. L. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223241 · Cited by 61
Unraveling Parkinson’s Disease Neurodegeneration: Does Aging Hold the Clues?
Coleman, C., & Martin, I. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223363 · Cited by 65
Mortal engines: Mitochondrial bioenergetics and dysfunction in neurodegenerative diseases
Joshi, A. U., & Mochly‐Rosen, D. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.010 · Cited by 57
Ponce, J., Ulu, A., Hanson, C., Cameron‐Smith, E., Bertoni, J. M., Wuebker, J., Fisher, A. L., Siu, K., Marmelat, V., Adamec, J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.780811 · Cited by 59
Maurya, S. K., Bhattacharya, N., Mishra, S., Bhattacharya, A., Banerjee, P., Senapati, S., & Mishra, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.654489 · Cited by 59
Novel Microglia-based Therapeutic Approaches to Neurodegenerative Disorders
Zhang, L., Wang, Y., Liu, T., Mao, Y. Q., & Peng, B. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-022-01013-6 · Cited by 59
Kanthasamy, A., Jin, H., Charli, A., Anantharam, V., & Kanthasamy, A. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.01.001 · Cited by 57
Bang, S., Lee, S., Choi, N., & Kim, H. N. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002119 · Cited by 57
Ghanbari, M., Darweesh, S. K. L., de Looper, H. W. J., van Luijn, M. M., Albert Hofman, D., Ikram, M. A., Franco, O. H., Erkeland, S. J., & Dehghan, A. (2015) · Human Mutation · doi:10.1002/humu.22943 · Cited by 54
Duffy, M. F., Collier, T. J., Patterson, J. R., Kemp, C. J., Fischer, D. L., Stoll, A. C., & Sortwell, C. E. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00621 · Cited by 56
Brainstem pathology in spasmodic dysphonia
Simonyan, K., Ludlow, C. L., & Vortmeyer, A. O. (2009) · The Laryngoscope · doi:10.1002/lary.20677 · Cited by 53
Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease
Zheng, T., & Zhang, Z. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105094 · Cited by 57
Oyanagi, K., Kinoshita, M., Suzuki‐Kouyama, E., Inoue, T., Nakahara, A., Tokiwai, M., Arai, N., Satoh, J., Aoki, N., Jinnai, K., et al. (2016) · Brain Pathology · doi:10.1111/bpa.12443 · Cited by 55
Aging enhances the neuroinflammatory response and α-synuclein nitration in rats
Choi, D., Zhang, J., & Bing, G. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.09.010 · Cited by 53
Neurons and Glia Interplay in α-Synucleinopathies
Mavroeidi, P., & Xilouri, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094994 · Cited by 55
Anyachor, C. P., Dooka, B. D., Orish, C. N., Amadi, C. N., Bocca, B., Ruggieri, F., Senofonte, M., Frazzoli, C., & Orisakwe, O. E. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.07.005 · Cited by 51
Xue, X., Zhang, W., Zhu, J., Chen, X., Zhou, S., Xu, Z., Hu, G., & Su, C. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14147 · Cited by 50
Nanomaterials as Microglia Modulators in the Treatment of Central Nervous System Disorders
Battaglini, M., Marino, A., Montorsi, M., Carmignani, A., Ceccarelli, M. C., & Ciofani, G. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202304180 · Cited by 54
Lack of Alpha-Synuclein Modulates Microglial Phenotype In Vitro
Austin, S. A., Rojanathammanee, L., Golovko, M. Y., Murphy, E. J., & Combs, C. K. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0439-9 · Cited by 51
Moran, L. B., Croisier, E., Duke, D. C., Kalaitzakis, M. E., Roncaroli, F., Deprez, M., Dexter, D. T., Pearce, R. K. B., & Graeber, M. B. (2007) · Acta Neuropathologica · doi:10.1007/s00401-006-0181-6 · Cited by 50
Self-citationZhu, Y., Bickford, P. C., Sanberg, P. R., Giunta, B. N., & Tan, J. (2008) · Rejuvenation Research · doi:10.1089/rej.2008.0757 · Cited by 49
Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches
Duarte, P., Cuadrado, A., & Leon, R. M. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_384 · Cited by 49
Bone Fracture Exacerbates Murine Ischemic Cerebral Injury
Degos, V., Maze, M., Vacas, S., Hirsch, J., Guo, Y., Shen, F., Jun, K., van Rooijen, N., Gressèns, P., Young, W. L., et al. (2013) · Anesthesiology · doi:10.1097/aln.0b013e31828c23f8 · Cited by 48
Binukumar, B. K., Shukla, V., Amin, N. D., Grant, P. G., Bhaskar, M., Skuntz, S., Steiner, J. P., & Pant, H. C. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-06-0415 · Cited by 48
Alpha Synuclein in Parkinson’s Disease
Kragh, C. L., Romero‐Ramos, M., Halliday, G. M., & Jensen, P. H. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_14 · Cited by 48
Kao, Y.-C., Wei, W., Tsai, K., & Wang, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010207 · Cited by 48
Sadeghian, M., Marinova-Mutafchieva, L., Broom, L., Davis, J. L., Virley, D. J., Medhurst, A. D., & Dexter, D. T. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.03.010 · Cited by 44
Self-citationDagra, A., Miller, D. R., Lin, M., Gopinath, A., Shaerzadeh, F., Harris, S., Sorrentino, Z. A., Støier, J. F., Velasco, S., Azar, J., et al. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00210-w · Cited by 51
Pradhan, S., & Andreasson, K. I. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.008 · Cited by 43
Zella, M. A. S., Metzdorf, J., Ostendorf, F., Maass, F., Muhlack, S., Gold, R., Haghikia, A., & Tönges, L. (2019) · Cells · doi:10.3390/cells8020105 · Cited by 43
Kim, J.-H., Jou, I., & Joe, E.-H. (2014) · Experimental Neurobiology · doi:10.5607/en.2014.23.2.148 · Cited by 43
The degeneration and replacement of dopamine cells in Parkinson’s disease: the role of aging
Rodrı́guez, M., Moráles, I., Rodriguez‐Sabate, C., Sánchez, A., Castro, R., Armas, J. M. B., & Sabaté, M. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00080 · Cited by 45
Neurobiological findings underlying depressive behavior in Parkinson’s disease: A review
Mendonça, I. P., Duarte-Silva, E. P., Chaves-Filho, A. J. M., Andrade‐da‐Costa, B. L. D. S., & Peixoto, C. A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106434 · Cited by 42
Gezer, A. O., Kochmanski, J. J., VanOeveren, S., Cole-Strauss, A., Kemp, C. J., Patterson, J. R., Miller, K. M., Kuhn, N. C., Herman, D. E., McIntire, A., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104947 · Cited by 45
Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation
Belloli, S., Morari, M., Murtaj, V., Valtorta, S., Moresco, R. M., & Gilardi, M. C. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00152 · Cited by 43
Guenoun, D., Blaise, N., Sellam, A., Roupret‐Serzec, J., Jacquens, A., Steenwinckel, J. V., Gressèns, P., & Bokobza, C. (2024) · Glia · doi:10.1002/glia.24664 · Cited by 41
Targeting STATs in neuroinflammation: The road less traveled!
Nabavi, S. M., Ahmed, T., Nawaz, M., Devi, K. P., Balan, D. J., Pittalà, V., Argüelles, S., Testai, L., Khan, H. Z., Sureda, A., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.12.004 · Cited by 43
O'Brien, J. A., & Austin, P. J. (2019) · Biomolecules · doi:10.3390/biom9080381 · Cited by 41
Porphyromonas gingivalis: a potential trigger of neurodegenerative disease
Huang, Z., Hao, M., Shi, N., Wang, X., Lin, Y., Yuan, H., & Wang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1482033 · Cited by 44
Bok, E., Cho, E. J., Chung, E. S., Shin, W.-H., & Jin, B. K. (2018) · Experimental Neurobiology · doi:10.5607/en.2018.27.4.309 · Cited by 36
Metadata
- Authors
- Croisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Graeber, Manuel B
- ORCID
- Dexter, David T
- Venue
- Journal of Neuroinflammation
- Published
- 2005-06-03
- Volume
- 2
- Issue
- 1
- Pages
- 14-14
- ISSN
- 1742-2094 (ISSN-L)
- PMC
- PMC1177985
- OpenAlex
- W1822935226
- Cited by
- 414
- References
- 34
- Citations by year
- 2026: 15 · 2025: 18 · 2024: 44 · 2023: 24 · 2022: 25 · 2021: 38 · 2020: 44 · 2019: 18 · 2018: 22 · 2017: 15 · 2016: 13 · 2015: 19 · 2014: 18 · 2013: 19 · 2012: 11
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Neuroinflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Parkinson's UK (G-4028)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, microglial activation, substantia nigra, MHC class II expression, CD68, microglial phagocytosis, neuroinflammation, disease duration, neuronal loss, postmortem brain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
